Overview In line with grant requirements, the C-SiG Pilot and Feasibility (P/F) Program: 1) Supports both new investigators just beginning their careers in digestive diseases research or innovative research proposals from experienced investigators who plan to change their area of research;ii) Provides investigators with vital funds to obtain preliminary data that support research grant applications from external agencies, especially NIH ROl grant submissions;and, iii) Provides mentorship, critical review of proposals, and coaching to improve the competitiveness of grant applications. We are strongly focused on junior investigators and Mayo Clinic has a sustained and rich tradition of facilitating the transition of junior investigators to independent scientists. As of February 2013, there were 1932 fellows (1311 MD (or equivalent), 130 MD/PhD, and 491 PhD) and 113 research trainees at Mayo Clinic Rochester. The Division of Gastroenterology and Hepatology (GIH) had a total of 82 fellows (36 fellows in the clinical training program, 5 fellows on our longstanding NIH Gl training grant, 41 postdoctoral research fellows) and 15 research trainees. GIH junior investigators comprise 26% of P/F applicants and 46% of the awardees. The C-SiG P/F Program works closely with the GIH Division and other Departments and Centers to help junior investigators achieve independent funding and to bring experienced investigators with C-SiG-relevant expertise into digestive disease research.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Mouchli, Mohamad A; Singh, Siddharth; Boardman, Lisa et al. (2018) Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflamm Bowel Dis 24:1074-1081
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Banales, Jesus M; Marzioni, Marco; LaRusso, Nicholas F et al. (2018) Cholangiocytes in health and disease: From basic science to novel treatments. Biochim Biophys Acta Mol Basis Dis 1864:1217-1219
Tarragó, Mariana G; Chini, Claudia C S; Kanamori, Karina S et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27:1081-1095.e10
Kim, Minsoo; Druliner, Brooke R; Vasmatzis, Nikolaos et al. (2018) Inferring modes of evolution from colorectal cancer with residual polyp of origin. Oncotarget 9:6780-6792
Druliner, Brooke R; Wang, Panwen; Bae, Taejeong et al. (2018) Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. Sci Rep 8:3161
Mansini, Adrian P; Lorenzo Pisarello, Maria J; Thelen, Kristen M et al. (2018) MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology 68:561-573
Moncsek, Anja; Al-Suraih, Mohammed S; Trussoni, Christy E et al. (2018) Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice. Hepatology 67:247-259
Allen, Alina M; Shah, Vijay H; Therneau, Terry M et al. (2018) The role of 3D-MRE in the diagnosis of NASH in obese patients undergoing bariatric surgery. Hepatology :
Dhanasekaran, Renumathy; Nault, Jean-Charles; Roberts, Lewis R et al. (2018) Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology :

Showing the most recent 10 out of 537 publications